Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEZS CVE:BCT NASDAQ:GSD CVE:IBT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEZSAeterna Zentaris$3.65+6.1%$3.52$3.96▼$12.00$6.54M1.557,305 shs2,461 shsBCTBriaCell TherapeuticsC$10.60-3.8%C$10.60C$3.50▼C$15.75C$168.68MN/A12,671 shs3,402 shsGSDGlobal System Dynamics$11.11$11.16$9.90▼$11.98$36.77MN/A7,280 shs2 shsIBTIBEX TechnologiesC$1.44C$1.44C$0.75▼C$1.45C$35.54M-0.0568,888 shs200 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEZSAeterna Zentaris+6.10%+6.41%+1.11%+48.98%-46.95%BCTBriaCell Therapeutics0.00%0.00%0.00%0.00%0.00%GSDGlobal System Dynamics0.00%0.00%0.00%0.00%0.00%IBTIBEX Technologies0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEZSAeterna ZentarisN/AN/AN/AN/AN/AN/AN/AN/ABCTBriaCell TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AGSDGlobal System DynamicsN/AN/AN/AN/AN/AN/AN/AN/AIBTIBEX TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEZSAeterna Zentaris 0.00N/AN/AN/ABCTBriaCell Therapeutics 0.00N/AC$15.0041.51% UpsideGSDGlobal System Dynamics 0.00N/AN/AN/AIBTIBEX Technologies 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEZSAeterna Zentaris$2.37M2.76N/AN/A$14.99 per share0.24BCTBriaCell TherapeuticsN/AN/AC$3.34 per share3.17C$3.60 per shareN/AGSDGlobal System DynamicsN/AN/AN/AN/A($1.84) per shareN/AIBTIBEX TechnologiesC$5.77M6.15C$0.92 per share1.56C$0.58 per share2.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEZSAeterna Zentaris-$16.55M-$14.86N/A∞N/A-760.32%-83.45%-45.76%8/11/2025 (Estimated)BCTBriaCell TherapeuticsN/A-C$0.38N/A∞N/AN/AN/AN/AN/AGSDGlobal System Dynamics-$790KN/A0.00∞N/AN/AN/A-2.30%N/AIBTIBEX TechnologiesC$3.10MC$0.1211.52∞N/A53.78%21.95%6.42%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEZSAeterna ZentarisN/AN/AN/AN/AN/ABCTBriaCell TherapeuticsN/AN/AN/AN/AN/AGSDGlobal System DynamicsN/AN/AN/AN/AN/AIBTIBEX TechnologiesN/A3.11%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEZSAeterna ZentarisN/A5.945.93BCTBriaCell Therapeutics0.05129.63128.68GSDGlobal System DynamicsN/A0.010.01IBTIBEX Technologies11.066.244.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEZSAeterna Zentaris0.73%BCTBriaCell TherapeuticsN/AGSDGlobal System Dynamics24.82%IBTIBEX Technologies19.05%Insider OwnershipCompanyInsider OwnershipAEZSAeterna Zentaris0.10%BCTBriaCell TherapeuticsN/AGSDGlobal System Dynamics62.81%IBTIBEX Technologies25.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEZSAeterna Zentaris201.79 million1.79 millionNo DataBCTBriaCell Therapeutics515.91 millionN/ANot OptionableGSDGlobal System DynamicsN/A3.31 million1.23 millionNot OptionableIBTIBEX TechnologiesN/A24.68 millionN/ANot OptionableBCT, IBT, GSD, and AEZS HeadlinesRecent News About These CompaniesSupplementary Review: IBEX Limited (IBEX), November 12, 2024November 12, 2024 | msn.comIBEX Announces Record First Quarter of Fiscal Year 2025 Financial ResultsNovember 7, 2024 | markets.businessinsider.comIBT's financial year in reviewOctober 1, 2024 | schroders.comSibex Launches Wave iX TranslateJuly 23, 2024 | tmcnet.comibex's Christy O'Connor Recognized as Top 10 Corporate Counsel Award WinnerMay 2, 2024 | tmcnet.comIBEX Completes Sale of the CompanyApril 8, 2024 | markets.businessinsider.comIBEX Technologies Inc.: IBEX Shareholders Approve Sale of the CompanyApril 4, 2024 | finanznachrichten.deIBEX Technologies Inc.March 23, 2024 | wsj.comIBEX Files Addendum to Management Proxy Circular for Sale of the Company at $1.45 Per ShareMarch 14, 2024 | finance.yahoo.comIBEX Technologies Inc (IBT) Earnings Dates & ReportsJanuary 1, 2024 | investing.comClosing Bell: Ibex Technologies Inc flat on Wednesday (IBT)October 18, 2023 | theglobeandmail.comClosing Bell: Ibex Technologies Inc flat on Thursday (IBT)October 6, 2023 | theglobeandmail.comClosing Bell: Ibex Technologies Inc down on Thursday (IBT)September 26, 2023 | theglobeandmail.comClosing Bell: Ibex Technologies Inc up on Tuesday (IBT)August 3, 2023 | theglobeandmail.comIs IBEX Technologies Inc.'s (CVE:IBT) Recent Stock Performance Tethered To Its Strong Fundamentals?June 15, 2023 | finance.yahoo.comMayfair Hits 52-Week High on NewsJune 14, 2023 | baystreet.caIBEX Technologies Inc. (IBT.V)May 23, 2023 | ca.finance.yahoo.comClosing Bell: Ibex Technologies Inc up on Friday (IBT)May 9, 2023 | theglobeandmail.comClosing Bell: Ibex Technologies Inc down on Friday (IBT)April 21, 2023 | theglobeandmail.comClosing Bell: Ibex Technologies Inc down on Wednesday (IBT)April 6, 2023 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCT, IBT, GSD, and AEZS Company DescriptionsAeterna Zentaris NASDAQ:AEZS$3.65 +0.21 (+6.10%) As of 07/8/2025Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.BriaCell Therapeutics CVE:BCTC$10.60 -0.42 (-3.81%) As of 12/30/2021BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.Global System Dynamics NASDAQ:GSDGlobal System Dynamics, Inc. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company focuses its search on the farming and national security sectors, including farming related operations and businesses that support the farming industry. The company was formerly known as Gladstone Acquisition Corporation. Global System Dynamics, Inc. was incorporated in 2021 and is based in Houston, Texas.IBEX Technologies CVE:IBTC$1.44 0.00 (0.00%) As of 04/5/2024IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, Germany, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; collagen ELISAs for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, it provides lyophilization services for making disposable medical device components; and custom fermentation and contract manufacturing services. It serves manufacturers of medical devices, quality control labs, low molecular weight heparin manufacturers, and academic research institutions. IBEX Technologies Inc. was incorporated in 1972 and is based in Montreal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Why Marvell Could Be the Smartest AI Bet Under $80 Autodesk Stock Ready to Rip? Q3 May Be the Turning Point Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
